This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Critical Care Device Stocks to Deflect the COVID-19 Curveball
by Debanjana Dey
Cantel (CMD), Hill-Rom (HRC), LeMaitre (LMAT) and Masimo (MASI) can prove to be prudent investment choices in the critical care industry of the MedTech sector.
Here's Why You Should Retain Integer Holdings (ITGR) Stock
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.
Allscripts' (MDRX) Solution Gets Selected by Revo Health
by Zacks Equity Research
Allscripts' (MDRX) Practice Management solution to improve financial and operational performance of all i-Health clinics of Revo Health.
Quest Diagnostics (DGX) Rides on Test Sales Amid Volume Woe
by Zacks Equity Research
Quest Diagnostics (DGX) enters into an agreement with the CDC to provide genomic sequencing to identify new mutations in and patterns of transmission of SARS-CoV-2.
Here's Why You Should Retain Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vince Surgical System. However, weakness at the Systems segment is a woe.
OPKO Health's (OPK) BioReference Extends Sports Partnerships
by Zacks Equity Research
OPKO Health's (OPK) BioReference expands its major league sports relationships with the announcement of COVID-19 testing agreement with MLB.
Orthofix (OFIX) Wins FDA Clearance for CONSTRUX Mini Ti System
by Zacks Equity Research
Orthofix's (OFIX) CONSTRUX Mini Ti Spacer System, designed with nanoscale surface is the first 3D-printed titanium interbody, was launched to enhance ACDF procedures.
Here's Why You Should Hold on to Ecolab (ECL) Stock for Now
by Zacks Equity Research
Ecolab (ECL) continues to gain traction for a solid product portfolio and cost-efficiency program. However, segmental weakness is worrisome.
BD (BDX) Receives FDA EUA for Combination Rapid Antigen Test
by Zacks Equity Research
BD (BDX) gets FDA EUA for new rapid, antigen test, which can distinguish between COVID-19, influenza A and influenza B in a single test.
Here's Why You Should Retain Integra LifeSciences (IART) Stock
by Zacks Equity Research
Investors are optimistic about Integra LifeSciences (IART) stock, owing to its strong international business growth and focus on portfolio optimization.
Here's Why You Should Retain Merit Medical (MMSI) Stock Now
by Zacks Equity Research
Merit Medical (MMSI) continues to gain traction on a solid product portfolio and strong international exposure. However, stiff competition is worrisome.
OPKO Health (OPK) BioReference Extends COVID-19 School Testing
by Zacks Equity Research
OPKO Health's (OPK) BioReference expands COVID-19 testing in schools to create a safer learning environment for students, teachers, staff and their families.
Is Cantel (CMD) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Cantel (CMD) possesses solid growth attributes, which could help it handily outperform the market.
Varian Medical (VAR) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Varian Medical (VAR) is optimistic about its prospective acquisitions and strength in Proton Therapy segment.
Will Walgreens Boots' (WBA) Retail Arm be Dull in Q2 Earnings?
by Zacks Equity Research
Walgreens Boots' (WBA) Retail Pharmacy International sales are likely to have remained dull in Q2 on difficult global market scenario.
Medtronic (MDT) Directional Lead for DBS System Gets CE Mark
by Zacks Equity Research
This SenSight system according to Medtronic (MDT), is set to enhance detection of local field potentials (LFPs).
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Hologic (HOLX) on its strong molecular diagnostic growth and robust international performance.
Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) backed by robust CAG and LPD revenues growth and strong global performance boosting the top line.
Looking for a Growth Stock? 3 Reasons Why Cantel (CMD) is a Solid Choice
by Zacks Equity Research
Cantel (CMD) could produce exceptional returns because of its solid growth attributes.
What Makes Cantel (CMD) a New Buy Stock
by Zacks Equity Research
Cantel (CMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CMD or ABMD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CMD vs. ABMD: Which Stock Is the Better Value Option?
Company News for Mar 10, 2021
by Zacks Equity Research
Companies In The News Are: THO, CMD, SFIX, TSLA.
Cantel Medical (CMD) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cantel (CMD) delivered earnings and revenue surprises of 61.22% and 9.39%, respectively, for the quarter ended January 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Cantel Medical (CMD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cantel (CMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Masimo's (MASI) iSirona to Boost Hospital Automation Platform
by Zacks Equity Research
Masimo's (MASI) iSirona helps in efficient workflow in hospitals by providing continuous connectivity, thereby helping clinicians to improve patient outcomes.